Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 20,384 shares of the biopharmaceutical company’s stock after acquiring an additional 2,234 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $21,428,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in REGN. SteelPeak Wealth LLC raised its stake in Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 692 shares in the last quarter. Atria Investments Inc increased its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after purchasing an additional 941 shares during the period. Mizuho Securities USA LLC raised its stake in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares in the last quarter. Tri Locum Partners LP lifted its holdings in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after purchasing an additional 8,949 shares during the period. Finally, Tidal Investments LLC grew its position in Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after buying an additional 711 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $738.00 on Monday. The firm has a market capitalization of $81.10 billion, a P/E ratio of 18.26, a PEG ratio of 2.84 and a beta of 0.15. The stock has a fifty day moving average of $945.07 and a 200-day moving average of $1,027.53. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on REGN. Citigroup initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target on the stock. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Leerink Partners restated a “market perform” rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.